Author Correction: Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation

被引：0

作者：

Chengyu Shi ^{[1
]}

Ying Wang ^{[2
]}

Minjie Wu ^{[3
]}

Yu Chen ^{[1
]}

Fangzhou Liu ^{[2
]}

Zheyuan Shen ^{[3
]}

Yiran Wang ^{[1
]}

Shaofang Xie ^{[2
]}

Yingying Shen ^{[3
]}

Lingjie Sang ^{[1
]}

Zhen Zhang ^{[2
]}

Zerui Gao ^{[3
]}

Luojia Yang ^{[1
]}

Lei Qu ^{[2
]}

Zuozhen Yang ^{[3
]}

Xinyu He ^{[4
]}

Yu Guo ^{[5
]}

Chenghao Pan ^{[1
]}

Jinxin Che ^{[6
]}

Huaiqiang Ju ^{[7
]}

Jian Liu ^{[1
]}

Zhijian Cai ^{[1
]}

Qingfeng Yan ^{[1
]}

Luyang Yu ^{[1
]}

Liangjing Wang ^{[1
]}

Xiaowu Dong ^{[1
]}

Pinglong Xu ^{[1
]}

Jianzhong Shao ^{[5
]}

Yang Liu ^{[4
]}

Xu Li ^{[5
]}

Wenqi Wang ^{[5
]}

Ruhong Zhou ^{[8
]}

Tianhua Zhou ^{[9
]}

Aifu Lin ^{[7
]}

机构：

[1] Zhejiang University,MOE Laboratory of Biosystem Homeostasis and Protection, College of Life Sciences

[2] Zhejiang University,Cancer Center

[3] Key Laboratory for Cell and Gene Engineering of Zhejiang Province,Innovation Institute for Artificial Intelligence in Medicine

[4] Zhejiang University,Hangzhou Institute of Innovative Medicine, Institute of Drug Discovery and Design, College of Pharmaceutical Sciences

[5] Zhejiang University,Key Laboratory of Structural Biology of Zhejiang Province, Westlake Laboratory of Life Sciences and Biomedicine

[6] Westlake University,Institute of Immunology

[7] Zhejiang University School of Medicine,Department of Gastroenterology, the Second Affiliated Hospital, School of Medicine and Institute of Gastroenterology

[8] Sun Yat-sen University Cancer Center,MOE Laboratory of Biosystems Homeostasis & Protection and Zhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, Life Sciences Institute

[9] State Key Laboratory of Oncology in South China,Department of Developmental and Cell Biology

[10] Collaborative Innovation Center for Cancer Medicine,Shanghai Institute for Advanced Study

[11] Zhejiang University-University of Edinburgh Institute (ZJU-UoE Institute),Department of Chemistry

[12] Zhejiang University School of Medicine,Institute of Quantitative Biology

[13] International Campus,Department of Cell Biology and Program in Molecular Cell Biology

[14] Zhejiang University,Department of Gastroenterology, the Second Affiliated Hospital, School of Medicine and Institute of Gastroenterology

[15] Zhejiang University,Breast Center of the First Affiliated Hospital, School of Medicine

[16] Zhejiang University,International School of Medicine, International Institutes of Medicine

[17] University of California,undefined

[18] Zhejiang University,undefined

[19] Colombia University,undefined

[20] Zhejiang University,undefined

[21] Zhejiang University School of Medicine,undefined

[22] Zhejiang University,undefined

[23] Zhejiang University,undefined

[24] The 4th Affiliated Hospital of Zhejiang University School of Medicine,undefined

[25] ZJU-QILU Joint Research Institute,undefined

来源：

Nature Communications | / 15卷 / 1期

关键词：

D O I：

10.1038/s41467-024-55049-5

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[31] Rigosertib promotes anti-tumor immunity via autophagic degradation of PD-L1 in colorectal cancer cells
Zhou, Xinyi
Fu, Dongliang
Yang, Hang
Le, Chenqin
Lu, Yier
Wei, Jingsun
Tang, Yang
Zhang, Jiawei
Yuan, Ying
Ding, Kefeng
Xiao, Qian
CANCER LETTERS, 2023, 577
[32] Suppression of PD-L1 release from small extracellular vesicles promotes systemic anti-tumor immunity by targeting ORAI1 calcium channels
Chen, Xi
Li, Jiaqi
Zhang, Ren
Zhang, Yao
Wang, Xiaoxuan
Leung, Elaine Lai-Han
Ma, Lijuan
Wong, Vincent Kam Wai
Liu, Liang
Neher, Erwin
Yu, Haijie
JOURNAL OF EXTRACELLULAR VESICLES, 2022, 11 (12)
[33] Design, synthesis, anti-tumor activity and mechanism of novel PROTACs as degraders of PD-L1 and inhibitors of PD-1/PD-L1 interaction
Zhang, Feng
Yu, Qimeng
Wu, Caiyun
Sun, Shishi
Wang, Yu
Wang, Rui
Chen, Zejie
Zhang, Hua
Xiong, Xuqiong
Awadasseid, Annoor
Rao, Guowu
Zhao, Xiaoyin
Zhang, Wen
BIOORGANIC & MEDICINAL CHEMISTRY, 2024, 111
[34] MicroRNA-4458 Regulates PD-L1 Expression to Enhance Anti-tumor Immunity in NSCLC via Targeting STAT3
Weixin Liu
Ruibao Liu
Ronghui Yuan
Xing Wang
Molecular Biotechnology, 2021, 63 : 1268 - 1279
[35] MicroRNA-4458 Regulates PD-L1 Expression to Enhance Anti-tumor Immunity in NSCLC via Targeting STAT3
Liu, Weixin
Liu, Ruibao
Yuan, Ronghui
Wang, Xing
MOLECULAR BIOTECHNOLOGY, 2021, 63 (12) : 1268 - 1279
[36] PD-L1 blockade enhances anti-tumor efficacy of NK cells
Oyer, Jeremiah L.
Gitto, Sarah B.
Altomare, Deborah A.
Copik, Alicja J.
ONCOIMMUNOLOGY, 2018, 7 (11):
[37] Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model
Kevin Durgan
Mohamed Ali
Paul Warner
Yvette E. Latchman
Cancer Immunology, Immunotherapy, 2011, 60 : 547 - 558
[38] Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model
Durgan, Kevin
Ali, Mohamed
Warner, Paul
Latchman, Yvette E.
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2011, 60 (04) : 547 - 558
[39] A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity
Albu, Diana I.
Wolf, Benjamin J.
Qin, Yan
Wang, Xianzhe
Ulumben, Amy Daniel
Su, Mei
Li, Vivian
Ding, Eirene
Gonzalo, Jose Angel
Kong, Jason
Jadhav, Ruturaj
Kuklin, Nelly
Visintin, Alberto
Gong, Bing
Schuetz, Thomas J.
ONCOIMMUNOLOGY, 2024, 13 (01):
[40] Targeting of exosomal PD-L1 to induce antitumor immunity
不详
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (08) : 1624 - 1624

← 1 2 3 4 5 →